Nvidia Corp vs Vaxcyte Inc. Common Stock — how do they compare? Nvidia Corp trades at $218.51 (market cap $5.52T), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Nvidia Corp is far larger — about 525.2× Vaxcyte Inc. Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nvidia Corp for 116 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| NVDA | PCVX | |
|---|---|---|
Market Cap | $5.52T | $10.51B |
Volume | 84,036,941 | 2,644,694 |
Sector | Technology | Health |
52-Week High | $239.27 | $73.82 |
52-Week Low | $165.17 | $40.32 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $5.49T | $9.14B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $221.51, down 2.13% today, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $221. Fundamentally, the company reported stellar revenue growth to $130.50 billion in 2025 and a net income margin of 63.66%, though valuation ratios like a P/E of 28.89 and P/S of 18.4 remain elevated. Recent news highlights AI-driven growth potential but also concerns over market saturation.
Outlook: Strong AI demand and earnings beats support long-term growth, but high valuations and competitive pressures pose risks. Analyst consensus is bullish with a $339.17 price target, suggesting significant upside if execution continues.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →